Ir
Non verificato

Ironwood Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network
28/05/2026
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Eventi
Fiere
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
1.00
27/05/2026
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
1.00
07/05/2026
Web e Social Network
Telefonia e Varie
Industria
Mercato azionario
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
1.00
30/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
1.00
04/03/2026
Web e Social Network
Eventi
Fiere
Biotecnologia
Farmaceutica
Salute
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
1.00
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
1.00
18/02/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
1.00
02/01/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Pubblico Esercizio/Vendita al dettaglio
Industria
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0